leisure time -WSS

leisure time

author：knowledge 2025-10-02 11:07:36 - browse：96378

Multiple syringes in a vial -- Pharma coverage from STAT — Adobe

Roughly two million Americans are expected to receive a cancer diagnosis this year. Some members of this already vulnerable group will wind up facing what physician Andrew Schuman recently called “a tragedy happening in slow motion” — an ongoing, nationwide shortage of critical oncology drugs that routinely save or extend the lives of children and adults.

Speaking at a March 22 Senate hearing on drug shortages, Schuman, a head and neck surgeon at the U.S. Department of Veterans Affairs, described the agonizing decisions that doctors must make when critical medicines are in short supply. “Should our limited vials go to an older woman who was just diagnosed with lung cancer? To a young man who had already been successfully taking it for his testicular cancer? Or a baby with neuroblastoma?” he asked. “As a doctor who has devoted my life to fighting cancer, it is hard to express how horrible it is to face this kind of tragedy.”

The dilemmas caused by cancer drug shortages are unfortunately nothing new. In the past decade alone, eight of the 10 drugs most commonly used to treat acute lymphoblastic leukemia, the most common kind of childhood cancer type of leukemia, have been temporarily unavailable. The problem has been getting worse: Nationwide shortages of critical drugs increased nearly 30% in 2022, soaring to their highest level in nearly five years, according to a report released by the Senate Homeland Security and Governmental Affairs Committee for the hearing. Oncology drugs currently in short supply include methotrexate, which treats breast and soft tissue cancers; cisplatin, which treats testicular, ovarian, bladder, head and neck, lung, and cervical cancers; fluorouracil, which treats skin cancer; Pluvicto, for prostate cancer; and the injectable bacillus Calmette-Guérin, for bladder cancer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Why Titanic fascinates society, still drawing tours to the wreckage

hotspot

WSS

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

With psoriasis trial ahead, Alumis raises $259 million

The PBM ad wars are taking over Washington, D.C.

Submersible on Titanic tour reported missing off Newfoundland with 5 people aboard

US intelligence assessment says Iran not currently developing nuclear weapons

A deep dive into Applied Therapeutics’ data, and questions on Cassava

leisure time

leisure time

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Amylyx ALS drug failure raises questions and concerns

New air purifier tech could be key to improving indoor air quality

How corporate America is slashing DEI workers amid backlash to diversity programs

In age of alternative facts, a scholarly course on calling out crap

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

United colonoscopy coverage change 'may cost lives,' doctors say

Trump seeks lengthy delay of classified docs trial, citing upcoming election

State Dept. review finds Biden bears some blame for Afghanistan failures

Sen. Bill Cassidy on how to lower drug prices

hotspot

Neutralizing antibodies against HIV shows promise in children

House panel to mark up pandemic

Sen. Paul opposes bill to ban Chinese biotechs

How to bring more disabled researchers into academia

First medicine developed to treat MASH expected to be approved soon

What to know about a major upcoming Wegovy heart health study

knowledge

hotspot

explore

leisure time